Key result
Serum exo-miR-92b-5p discriminates HFrEF patients from healthy controls with ~83% specificity.
Why the study?
Does serum exo-miR-92b-5p serve as a diagnostic biomarker for HFrEF in patients hospitalized for acute heart failure?
Case-Control
Does serum exo-miR-92b-5p serve as a diagnostic biomarker for HFrEF in patients hospitalized for acute heart failure?
Serum exosomal miR-92b-5p is elevated in HFrEF patients and correlates with echocardiographic parameters, suggesting its potential as a diagnostic biomarker.
Answers are grounded in this paper and cite their sources.
Serum exo-miRNAs may aid acute HFrEF diagnosis; leaves open clinical utility pending larger prospective validation.
BACKGROUND: Circulating microRNA (miRNA) biomarkers have been extensively reported in cardiovascular diseases (CVDs). However, serum exosomal miRNA (exo-miRNA) as biomarker in patients with heart failure (HF) with reduced ejection fraction (HFrEF) remain largely unexplored. We sought to investigate the potential of three types of serum exo-miRNAs as biomarkers for diagnosis in HFrEF patients who were admitted in hospital because of acute heart failure (AHF). METHODS: AHF and acute decompensated HF, and 30 volunteers as control group (CG) from 2015 to 2017 were enrolled in this study. Serum exo-miRNAs were extracted and analyzed by NaNOZS-90, electron microscopy, and western blotting. Three types of serum exo-miRNAs (exo-miR-92b-5p, -192-5p, and -320a) were assessed by quantitative real time polymerase chain reaction (qRT-PCR). RESULTS: in the qPCR assay. The data showed that exo-miR-92b-5p was elevated in HFrEF patients compared with controls. Moreover, exo-miR-92b-5p was inversely correlated with the left ventricular fraction shortening (LVFS) and left ventricular ejection fraction (LVEF), whereas it was positively correlated with left atrial diameter (LAD), left ventricular diastolic diameters (LVDD) and systolic diameters (LVSD). A receiver operating characteristic (ROC) curve was generated for discrimination between HFrEF patients and controls based on exo-miR-92b-5p (P<0.001, sensitivity =71.4%, specificity =83.3%). CONCLUSIONS: Exo-miR-92b-5p levels in the serum may serve as a marker for HFrEF diagnosis.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2018) conducted a case-control in Heart failure with reduced ejection fraction (HFrEF). Serum exo-miR-92b-5p vs. Healthy volunteers was evaluated on Discrimination between HFrEF patients and controls (Sensitivity 71.4%, Specificity 83.3%, p=<0.001). Serum exo-miR-92b-5p levels discriminated HFrEF patients from healthy controls with a sensitivity of 71.4% and specificity of 83.3%.
Synapse has enriched 10 related papers. Consider them for comparative context: